GLP1R and type 2 diabetes mellitus: In 14 patients with type 2 diabetes mellitus, gastrointestinal motility was evaluated by capsule endoscopy before and after the administration of liraglutide, a GLP1 receptor agonist, and it was observed that liraglutide suppressed the patients' duodenal and small intestinal motility [20].